文献速递淋巴瘤

非霍奇金淋巴瘤一线CHOP或R-CHOP治疗的心血管不良事件:系统综述与荟萃分析

Cardiovascular adverse events in patients with non-Hodgkin lymphoma treated with first-line cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP with rituximab (R-CHOP): a systematic review and meta-analysis.
PubMed 文献 · Lancet Haematol · 2020-03-02

BACKGROUND: Patients treated for non-Hodgkin lymphoma are at risk of cardiovascular adverse events, with the risk of heart failure being particularly high.…

要点

  • 提示常规心脏监测下心衰常被漏诊,化疗期间及化疗后应加强心脏监测。

核心结论

  • 接受一线R-CHOP或CHOP的非霍奇金淋巴瘤患者中,心脏监测下报告的心力衰竭比例明显增加,提示该并发症常被漏诊。
  • 应提高临床医生对该并发症的认识,并强调化疗期间及化疗后心脏监测的必要性。
  • 在症状前期及时启动心力衰竭治疗可减缓向更晚期心力衰竭的进展。

研究设计与样本

  • 系统综述与荟萃分析,检索PubMed、EMBASE和Cochrane Library自建库至2019年6月3日的文献。
  • 纳入接受一线R-CHOP或CHOP治疗的成人非霍奇金淋巴瘤临床研究,包括弥漫大B细胞淋巴瘤、滤泡性淋巴瘤、套细胞淋巴瘤、外周T细胞淋巴瘤及非霍奇金淋巴瘤非特指型。
  • 主要结局为3-4级心血管不良事件和心力衰竭的患者比例,采用单样本比例荟萃分析,并按CHOP或R-CHOP周期数、周期间隔、年龄和性别进行亚组分析。

主要发现

  • 137项研究中,53项(39%)因结局数据不完整被评为高偏倚风险,54项(39%)因选择性报告被评为高偏倚风险。

临床怎么用

  • 对接受一线CHOP或R-CHOP的非霍奇金淋巴瘤患者,应在化疗期间及化疗后加强心脏监测以及时发现心力衰竭。
  • 对监测发现的无症状心力衰竭应在症状前期及时启动治疗,以减缓向更晚期心力衰竭的进展。
  • 临床医生应提高对CHOP或R-CHOP相关心力衰竭的认识,避免漏诊。

局限性

  • 53项(39%)研究因结局数据不完整存在高偏倚风险,54项(39%)因选择性报告存在高偏倚风险。
  • 仅纳入英文发表文献,非英文摘要和文章被排除。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients treated for non-Hodgkin lymphoma are at risk of cardiovascular adverse events, with the risk of heart failure being particularly high. A regimen of cyclophosphamide, doxorubicin, vincristine, and prednisone, with (R-CHOP) or without (CHOP) rituximab is the standard first-line treatment for aggressive non-Hodgkin lymphoma, and doxorubicin and cyclophosphamide are both associated with left ventricular dysfunction. The aim of this systematic review and meta-analysis was to evaluate the cardiovascular toxicity of this regimen. METHODS: We systematically searched PubMed, EMBASE, and the Cochrane Library from database inception to June 3, 2019, for clinical trials and observational studies in adult patients with non-Hodgkin lymphoma (diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma, and non-Hodgkin lymphoma not otherwise specified) that received first-line treatment with R-CHOP or CHOP. Studies reporting on cardiovascular adverse events and treatment-related cardiovascular mortality were included. Abstracts and articles not written in English were excluded. The main outcomes were the proportion of patients with grade 3-4 cardiovascular adverse events and heart failure. Meta-analyses of one-sample proportions were done in all patients receiving CHOP or R-CHOP. Subgroup analyses on summary estimates were done to determine the effect of number of CHOP or R-CHOP cycles, cycle interval, age, and sex. FINDINGS: Of 2314 identified entries, 137 studies (21 211 patients) published between April, 1984, and June, 2019 were eligible (9541 patients treated with CHOP, 11 293 patients treated with R-CHOP, 377 both regimens used in the study; median follow-up 39·0 months [IQR 25·5-52·8]). From the included studies, 85 subgroups were treated with CHOP, 76 with R-CHOP, and in four studies both CHOP and R-CHOP were used without a subdivision in separate groups. The pooled proportion for grade 3-4 cardiovascular adverse events, based on 77 studies (n=14 351 patients), was 2·35% (95% CI 1·81-2·93; heterogeneity test Q=326·21; τ2=0·0042; I2=71·40%; p<0·0001). For heart failure, the pooled proportion, based on 38 studies (n=5936 patients), was 4·62% (2·25-7·65; heterogeneity test Q=527·33; τ2=0·0384; I2=95·05%; p<0·0001), with a significant increase in reported heart failure from 1·64% (95% CI 0·82-2·65) to 11·72% (3·00-24·53) when cardiac function was evaluated post-chemotherapy (p=0·017). 53 (39%) of 137 studies were rated as having high risk of bias for incomplete outcome data and 54 (39%) for selective reporting. INTERPRETATION: The considerable increase of reported heart failures with cardiac monitoring, indicates that this complication often remains undiagnosed in patients with non-Hodgkin lymphoma who received first-line R-CHOP or CHOP. Our findings are of importance to raise awareness of this complication among clinicians treating patients with non-Hodgkin lymphoma and stresses the need for cardiac monitoring during and after chemotherapy. Prompt initiation of treatment for heart failure in the presymptomatic phase can mitigate the progression to more advanced heart failure stages. FUNDING: None.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Linschoten M, Kamphuis JAM, van Rhenen A, et al. Cardiovascular adverse events in patients with non-Hodgkin lymphoma treated with first-line cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP with rituximab (R-CHOP): a systematic review and meta-analysis. Lancet Haematol. 2020. PMID: 32135128. doi:10.1016/S2352-3026(20)30031-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。